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ABSTRACT 
Photodynamic therapy (PDT) is now an established method to treat superficial basal cell 
carcinoma (BCC), Bowen’s disease (BD) and actinic keratosis (AK). The main advantage of 
PDT is that it is non-invasive and gives excellent cosmetic results; although the majority of 
the patients do experience some degree of pain, which can sometimes be extreme. 
Fluorescence diagnostics (FD) is a method to diagnose mainly BCC, which is the most 
common type of tumour within the class of non-melanoma skin cancer (NMSC) and accounts 
for about 80% of all skin tumours. This technique can be used as an in vivo pre-surgical 
diagnostic tool, which can help to detect occult tumour borders of ill-defined BCCs.  
 
In the first study (Paper I), the impact of fluence rate and spectral range on the primary 
treatment outcome and bleaching rate in AKs using aminolaevulinic acid (ALA)-PDT was 
studied. Pain during treatment was also registered. The results imply that the photobleaching 
rate and primary treatment outcome were dependent on the fluence rate and that a low fluence 
rate (30 mW/cm2) appears preferable. In the second study (Paper II), risk factors related to 
pain during PDT for AK were investigated. The most important factors relating to the 
experience of pain seem to be the size and “redness” of the lesion. No significant pain relief 
with capsaicin was seen. In the third study (Paper III), the transdermal penetration of ALA 
and methyl-aminolaevulinate (MAL) in vivo were investigated using a microdialysis 
technique. The results imply that there is no significant difference in transdermal penetration 
of ALA and MAL in tumour tissue. Detectable levels of the drug were not obtained in almost 
50% of the lesions where catheters were inserted 1-1.9 mm into the lesion. Curettage was not 
found to affect the interstitial concentration, indicating that penetration of the drug might 
indeed be a problem when treating BCCs thicker than 1 mm. In the final study presented 
within this thesis (Paper IV), the fluorescence contrast in patients undergoing MAL-PDT for 
superficial BCCs was evaluated. The MAL fluorescence contrast obtained between the 
tumour and normal skin was also compared to that obtained in a previous study using ALA. In 
both cases it was possible to identify areas in the fluorescence images corresponding to a 
tumour and to surrounding normal skin. The mean fluorescence contrast with MAL, however, 
was significantly higher than the mean fluorescence contrast after application of ALA. Thus, 
MAL generally renders a higher tumour contrast compared to ALA in superficial BCCs. No 
correlation between fluorescence and treatment response could be observed.  
 
The results of this thesis prove that PDT, using either ALA or MAL, is effective in the 
treatment of thin non-melanoma skin cancer and pre-cancer. These results further suggest that 
lower fluence rate should be considered as a precaution to minimise pain response when 
treating large and inflammatory lesions, although more study is needed. When performing 
FD, MAL is the best option and lack of treatment response cannot be connected to 
fluorescence but maybe due to the fact that the pro-drug does not successfully penetrate into 
the deeper parts of the tumour. 
Key words: actinic keratosis, aminolaevulinic acid, fluorescence contrast, methyl-
aminolaevulinic acid, microdialysis, non-melanoma skin cancer, pain, photodynamic therapy  
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1. INTRODUCTION 
 
1.1. Human skin 
The skin is the largest organ of the human body, see figure 1. It protects the body from water 
loss, regulates body temperature and is the outer barrier against heat, cold, and bacteria. 
Stretched out it has an area of approximately 2 m2. The skin is divided into three main layers: 
the epidermis, the dermis and the subcutis1. This thesis will deal mostly with the two upper 
layers of the skin as this is where photodynamic therapy (PDT) and fluorescence diagnostics 
(FD) take place.  
 
The epidermis, is the thin top layer approximately 0.1 mm thick1. The deepest part is the 
stratum basale, containing immature cubic cells of the keratinocytes. As these cells divide and 
mature, they move to more superficial layers, first to the stratum spinosum and then to the 
stratum granulosum where these cells become more extended. Finally, the keratinocytes 
become hornified in the most superficial layer, stratum corneum, where they lose their nuclei. 
This horny layer forms the “semi-permeable membrane” of the body and protects it from 
water loss 2.  In the stratum basale there are also dendritic cells which are placed at an interval 
of  every 10th cell, so called melanocytes 3, forming the melanosomes which contain pigment. 
It is these melanosomes that are transported out to the surrounding keratinocytes and protect 
them from UV-radiation. Each melanocyte will support 36 keratinocytes with melanosomes 4. 
Another dendritic cell is the Langerhans cell. This cell is an antigen presenting cell which 
processes exogenous antigens which are then presented to naïve T-cells. The Langerhans cells 
account for approximately 3-6% of the epidermal cells1. 
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The dermo-epidermal junction separates the epidermis from the dermis. The papillary dermis 
is the upper part of the dermis where capillaries extend from the superficial plexus of blood  
vessels, dividing the papillary dermis part from the reticular dermis. 
Figure 1.  Skin anatomy   (Photo : Lena Mölne)
The dermis is composed mostly of fibres produced from fibroblasts.  These fibres (elastin, 
collagen, reticulin) are surrounded by a liquid ground substance consisting of water, 
glucosaminoglycans and hyaluronic acid. Together these substances provide the elasticity and 
12
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strength of the skin. In the dermis, the blood vessels also support the epidermis and the dermis 
with nutrients and oxygen.  
 
The subcutis, which is the deepest part of the skin, mainly consists of lipocytes and some 
blood vessels. The subcutis functions as an energy reservoir and thermo-insulator of the body. 
To some extent it also protects the body from trauma. 
 
1.2. Skin cancer  
There are two main groups of skin cancers: melanoma skin cancer (MSC), and non-melanoma 
skin cancer (NMSC); although some other rare forms of cancer do exist such as 
dermatofibrosarcoma protuberans, Merckel cell carcinoma and atypical fibroxanthoma. This 
thesis, however, will focus on the two common types of cancer, i.e., MSC and NMSC. 
 
1.2.1 Melanoma skin cancer 
MSC originates from pigmented cells, the so called melanocytes. The pigment, melanin, 
absorbs light mainly in the visible spectrum (400-600nm), the same spectrum of light that is 
used in both PDT and FD. Therefore only red light (around 635nm) is theoretically suitable 
for PDT of melanoma cells. This treatment is not recommended for melanoma cells, however, 
as while in vitro melanoma cells have responded to the treatment, in vivo melanoma cells 
respond very poorly5,6. The FD-method is not applied to pigmental skin cancer as the 
absorption spectrum for FD is UV-blue-light, i.e., the same spectral region that melanin 
absorbs light.  
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1.2.2 Precursors to non-melanoma skin cancer  
1.2.2.1 Actinic keratosis 
Actinic keratosis (AK) is the earliest precursor for squamous cell carcinomas, SCCs, although 
few AKs actually proceed to SCCs. Approximately 25% of AKs regress spontaneously,  while 
about 10% will become SCCs 7. The AK consists of disordered keratinocytes with cytological 
atypia, parakeratosis and loss of the stratum granulosum. Clinically, AKs can be classified in 
three grades: I) those not easily seen but with a rough feeling of the skin, II) those easily seen 
as a red scaly area with a rough skin and finally III) obvious, hyperkeratotic, indurated red 
scaly areas 8. Often, the AKs derive from sun-exposed and sun-damaged skin 9. The AK’s 
can, therefore, appear over an extensive area which is often described as field cancerization, 
i.e., a field full of potential SCCs.  
 
1.2.2.2 Squamous cell carcinoma in situ 
Squamous cell carcinoma in situ, i.e., Bowen’s disease, is the final precursor for squamous 
cell carcinoma. Histopathologically, the atypical keratinocytes constitute the whole of the 
epidermis but have not yet broken the basal membrane. After the breakage of the basal 
membrane they have formally become a true SCC. Bowen’s disease often arises from actinic 
keratosis. Clinically it can imitate eczema and appear as a red scaly well-defined area. Usually 
it is located on sun-exposed areas such as the upper extremities, ears and cheeks 10,11. SCC has 
a clear relationship to sun-exposure, i.e., UV-B radiation. Other risk factors include 
immunosuppressive medication, HPV, chronic scarring and inflammation of the skin11-13. All 
non-melanoma skin cancer and NMSC-precursors are more common in males than females9.  
 
 
 
14
 15
1.2.3 Non-melanoma skin cancer 
1.2.3.1 Basal cell carcinoma  
Basal cell carcinoma (BCC) represents approximately 80% of all non-melanoma skin cancers. 
BCCs are not thought to have any precursors, i.e., they arise de novo.  Risk factors for BCCs 
include cumulative and intense “bursts” of exposure to UV-light, hereditary factors including 
skin type, exposure to arsenic, radiation and immunosuppressive medication. Most BCCs 
(85%) appear on the head and neck and (fortunately) very rarely metastasize. Usually growth 
is slow. For all BCCs, the mean age of occurrence is between 60-70 years of age14. 
 
There are three main forms of BCCs, defined according to their histological growth: nodular, 
superficial and infiltrative including morpheiform.  
 
Nodular BCCs account for approximately 50-60% of all BCCs. These are more common in 
males and occur mostly on the head and neck. Clinically, they appear as pinkish nodular shiny 
tumours, often with telangiectasia. Histopathologically, the tumour nests extends into the 
dermis. 
 
Superficial BCCs account for approximately 25% and are more common in younger females. 
Superficial BCCs tend to be more equally distributed on the body, often on the trunk in men 
and upper extremities in females. They appear as maculae and have a pinkish colour with 
associated scaling. Tumour nests grow in connection to the basal cell layer and the hair 
follicles.  
 
Infiltrative including morpheiform BCCs account for approximately 15 % of all BCCs. These 
are mostly situated in the head and neck region and are the most aggressive form of BCC 
1
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which grows in an infiltrative manner. Clinically morpheiform BCCs can look like a scar with 
diffuse extension and ill-defined borders. This is one of the reasons why they are often not 
discovered until very late when they may have extended into the subcutis, muscle tissue or 
bone. 
 
1.2.3.2 Basal cell nevus syndrome (Gorlin syndrome) 
Nevoid basal cell carcinoma syndrome (NBCCS) is caused by mutations in the PTCH1 gene. 
The PTCH1 gene encodes the principle receptor for the Hedgehog signalling pathway. 
NBCCS is equally common in males and females. Mean age of onset is 25 years old but the 
syndrome can occur early in childhood. The main clinical manifestations (major criteria) 
include: multiple basal cell carcinomas (BCCs), odontogenic keratocysts of the jaws, 
hyperkeratosis of palms and soles seen as palmar and plantar pits, skeletal abnormalities, first 
degree relatives with NBCCS. Minor criteria include: facial dysmorphism, radiological 
abnormalities, medulloblastoma and ovarian fibroma. Diagnosis is set if two major criteria are 
fulfilled or one major criterion and two minor criteria. The BCCs are most commonly located 
on the face, back and chest and are more frequent on sun-exposed areas15. 
 
1.2.3.3 Squamous cell carcinoma  
Squamous cell carcinoma (SCC) is a tumour that derives from the keratinocytes in the 
epidermis. Clinically they appear in actinic skin in elderly people growing to fully developed 
skin cancer invading the dermis. SCCs often appear to be a plaque growing to form a nodule 
and finally ulceration. The main distribution is on sun-exposed areas such as the head, neck 
and upper extremities including the dorsum of the hands. SCCs have a clear relationship to 
sun-exposure, i.e., UV-B radiation. Other risk factors include: immunosuppressive 
medication, HPV, chronic scarring and inflammation of the skin 12,13. SCCs are more common 
16
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in males than females9. In a large study, Brantsch et al. (2008)11 found the mean age of onset 
to be approximately 70 years of age 
 
Generally SCCs are slow-growing with a potential to metastasize, especially when located on 
the ears and lips. SCCs can be well, moderately or poorly differentiated; the last of the three 
types having the worst prognosis. 
 
1.2.3.4 Keratoacanthoma 
Keratoacanthoma (KA) is a tumour with a peak incidence between 50-69 years in which both 
genders are equally affected. Ethiology is unknown but one theory is that these tumours are 
derived from hair follicles because of the large amount of keratin stored there. Clinically, they 
appear mostly on sun-exposed areas such as on the face, neck and hands. Risk factors include 
a light (pale) complexion, UV-radiation, trauma, chemical carcinogens and immuno-
suppressive medications16,17.  
 
These tumours grow rapidly up to 25 mm in size in 6-8 weeks and start as a small pink 
macule, which forms a nodule with a keratin-filled volcano-like crater. During involution, 
approximately 50% of all tumours disappear. Some lesions may exist for years before 
disappearing. Typically the whole cycle takes 4-9 months. An atypical KA can, however, be 
very aggressive. Microscopically it is very difficult to differentiate between a KA and an 
SCC.  KA is therefore treated as an SCC18. 
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1.3 Treatment of non-melanoma skin cancer and its precursors  
National guidelines refer to the treatment of all precursors and NMSC19-22. 
 
There is an ongoing debate about the importance of treating all actinic keratoses. However 
considering the above facts most authors recommend treatment. The treatment of choice is 
often dependent on the size of the lesion. Large areas of AKs are very suitable for PDT, but 
even topical therapy, such as imiquimod and 5-FU, is effective23. Sometimes diclofenac 24can 
also be used, but this seems to be less effective. However, PDT is typically a “one-shot 
therapy”, and is therefore safer than topical treatment. Further, several studies have shown 
compliance with recommended drugs is low which compromises their function25,26. 
Cryosurgery with liquid nitrogen is the preferred treatment of choice for single AK lesions; 
but is not recommended as treatment for field cancerization. 
 
Squamous cell carcinoma in situ is a superficial lesion suitable for skin excision, cryosurgery 
or electro-dessiccation with curettage, PDT or 5-FU. Choice of treatment depends on location, 
size, extent of the lesion and local guidelines. 
 
Basal cell carcinomas are treated according to their histological growth pattern (nodular, 
superficial and infiltrative (morpheiform)) and local guidelines.  
 
Nodular BCCs can either be excised, or treated with cryosurgery or electro-dessiccation 
preceded by curettage. PDT can be considered for thin nodular BCCs.  
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For superficial BCCs, PDT and imiquimod are excellent therapies due to the good cosmetic 
outcome. Cryosurgery is also an option, and sometimes excision is used.  
 
Finally for morpheiform BCCs with infiltrative growth, Mohs micrographic surgery is 
recommended. However, excision with clear margins according to local guidelines can also 
be performed27.  
 
Nevoid basal cell carcinoma syndrome (Gorlin syndrome) 
The treatment of BCCs is based on the histopathological growth. Surgery is indicated when 
the number of lesions is limited or with aggressive growth. As the number of BCCs increases, 
individual schemes may be needed and other treatments including laser ablation, 
photodynamic therapy and topical chemotherapy, are often used. However, radiotherapy 
should be avoided. Not only are recurrences and incomplete clearance rates high when using 
radiotherapy but the PTCH1 gene is also susceptible to the radiation and may be prompted to 
produce more BCCs. Even in healthy patients, induction of BCCs in skin treated with 
ionizated radiation have been reported15,28. 
 
Squamous cell carcinoma and keratoacanthoma should always be excised with margins based 
on histologic investigation and local guidelines. 
 
Radiotherapy is an option in the treatment of NMSC but is seldom used due to the 
disadvantages with scarring and the high rate of recurrence. Recurrences occurring after 
radiotherapy of BCCs often require Mohs surgery27,29. 
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1.4. Photodynamic therapy (PDT) 
 
1.4.1 History and basic aspects of PDT  
The history of PDT is more than a hundred years old. In the 1890s a Danish scientist, Niels 
Finsen, treated skin tuberculosis with sunlight. The treatment was successful and for this 
discovery he received the Nobel Prize in 1903. The success of Niels Finsen created scientific 
interest worldwide and in the beginning of the 20th century an intensive research period, 
involving the use of sunlight, began.  In 1903 two scientists, Hermann von Tappeiner and 
Albert Jesionek, treated BCCs with the dye eosin and afterwards irradiated with visible light. 
This treatment also proved to be successful 30 .  
 
In the 1970s Thomas Dougherty duplicated the work of von Tappeiner and Jesionek but used 
hematoporphyrin derivative (HPD) in the treatment of skin cancer. HPD was administered 
systemically, the reason for this being that the HPD molecules were too large to be able to 
penetrate the skin topically31. The major disadvantage of this treatment was the 
photosensitization of the skin for weeks following initial treatment31.  In 1990 Kennedy and 
Poitiers described what would become today’s modern topical PDT using a porphyrin-
precursor, aminolaevulinic acid, ALA, as a sensitizer for superficial BCCs and then 
irradiating the effected area with visible light32.  
 
The basic principles of PDT are the administration of a pro-drug or a photosensitizer such as 
ALA, either topically or intravenously, to rapidly dividing cells such as, e.g., atypical cells 
and tumour cells. When sufficient sensitizer has accumulated in the target cells, the effected 
20
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area is irradiated with a regulated dose of light, with an appropriate wavelength to match the 
photosensitiser’s peaks of absorption. An energy transfer between the sensitiser and molecular 
oxygen will take place which will form reactive oxygen species (ROS), mainly singlet 
oxygen. The cells are then destroyed. However, the exact mechanism for the destruction of 
the cells is not yet fully understood, although the mitochondrial membrane is most likely 
disrupted when using ALA-PDT. Since both PDT and FD are relatively new techniques they 
still need to be improved and further investigations are needed to fully understand the 
mechanism of action. 
 
1.4.2 Photosensitization 
1.4.2.1 Photosensitization using ALA and MAL 
The δ-5-aminolaevulinic acid (ALA) or its methyl-ester, methyl-aminolaevulinate (MAL) are 
most commonly used for PDT in dermatology. Other sensitizers from the chlorine-, 
phtalocyanine- and phenothiazinium- families may also be used. These will not be further 
discussed in this thesis. 
By using the haem biosynthesis in the cells the final photosensitizer, protoporphyrin IX, 
PpIX, is endogenously formed, see figure 2. As seen in figure 2, the metabolization is 
localised to the mitochondria and the cytosol. In the haem biosynthesis ALA is syntesized by 
succinyl-CoA and glycine in the mithochondria, which is regulated by a negative feedback 
from the last step where iron is incorporated to build haem. By adding ALA exogenously, the 
first step and regulation are bypassed and more PpIX can be formed.  
 
The PpIX is believed to accumulate more rapidly in the tumour cells than in the normal cells 
due to an altered skin barrier in the tumour cells. Further, differences in enzymes between 
tumour cells and normal cells cause more rapid accumulation of PpIX. Finally, tumours may 
2
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have increased blood perfusion fostering the accumulation of PpIX. In tumour cells the skin 
barrier is disrupted 33 and is thought to have a more rapidly functioning porphobilinogen 
deaminase (PBGD) and a less rapidly functioning ferrochelatase (FC) than normal cells 34-36. 
Therefore when enough PpIX is formed in the tumour cells, the normal cells have still not 
accumulated enough photosensitizer to be damaged by the photochemical reaction.  
 
 
Extra-cellular fluid Cytosol
Cell membrane
Mitochondria
Glycine Succinyl-CoA
5-aminolaevulinic
acid synthase
ALA
ALA
Porphobilinogen
Porphobilinogen
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Hydroxymethylbilane
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PpIX
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Figure 2.   Haem biosynthesis 
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1.4.2.2 Penetration of the pro-drug  
One of the disadvantages with topical PDT is that the administration of the pro-drug can be 
difficult. ALA is a hydrophilic and charged salt-substance. Therefore, penetration deep into 
the skin can be difficult since the stratum corneum consists of cell remnants, with 
hydrophobic cell membranes and will not easily permit the ALA to diffuse passively. Once 
the stratum corneum is penetrated, however, ALA can travel two pathways, either between 
the cells in the extra-cellular fluid as the extra-cellular fluid is more hydrophilic, or through 
active transport of ALA into the cells via the GABA-receptors37. MAL is more hydrophobic 
and will hypothetically more easily penetrate the stratum corneum and through the cell 
membrane. The stratum corneum is very hydrophobic, therefore in theory there is a greater 
risk that MAL will be trapped there and therefore not be able to penetrate deeper than ALA. 
Furthermore in contrast to ALA, MAL is not actively transported into the cells via the 
GABA-receptors37 therefore ALA but not MAL can be transported directly into the nerve-end 
fibres and make the skin area more sensitised. This may be one reason why greater pain is 
experienced during ALA-PDT (see the section 1.4.7).  
 
As there is a limit to how far both ALA and its esters can reach into the skin there is some 
uncertainty whether they can reach deep enough to treat the whole tumour and therefore only 
superficial lesions are suitable candidates for PDT. This is thought to be one of the 
explanations for the limited cure rate of nodular BCCs using ALA-PDT38,39 
 
There are methods for recording the depth that the pro-drug and PpIX have reached. Almost 
all of these methods have been developed in in vitro studies. The pro-drug is applied topically 
on the normal skin or on tumour tissue. After a specified period of time a biopsy is taken and 
examined in a fluorescence microscope. Peng et al. 40 detected PpIX, when examining six 
2
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(human) biopsies, down to a depth of  2 mm in only one of the biopsies. Ahmadi et al. 41 in an 
in vitro study using scintillation spectroscopy and a precise tissue sectioning protocol found 
that out of five human BCC-biopsies only two showed ALA at 2 mm depth. Until now there 
has been only one in vivo study, by Wennberg et al.42, where ALA was detected in superficial 
BCCs by microdialysis at a depth of 0.5 mm. 
 
1.4.2.3 Pre-treatment of the lesion  
To overcome the difficulties of penetration, a light curettage of the lesion is widely performed 
without any bloodshed. The rationale is to remove the stratum corneum and hyperkeratoses to 
ensure easier penetration although different studies have shown varying results. Other 
techniques such as tape-stripping may also be used. Van den Akker 43 described in a study in 
2003  that tape-stripping of normal nude mouse skin increased the PpIX-concentration 
implying that stratum corneum is an important barrier for the pro-drugs. This was supported 
by a study from Gerritsen44 and in a study by Smits et al. 45 who showed a negative 
correlation between the thickness of stratum corneum and a higher amount of superficial 
PpIX measured indirectly by fluorescence diagnostics. As for superficial BCCs and BDs it 
does not seem necessary to pretreat. Moseley et al. 46 found in 2008 that there was no 
significant difference in superficial PpIX fluorescence in superficial BCC and BD with or 
without prior curettage of the lesion nor were there any significant differences in the cure rate. 
Still the use of curettage before applying the pro-drug is widely performed and further studies 
on this subject are required to confirm the earlier results. 
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1.4.2.4 Treatment time with ALA and MAL 
Accumulation  of PpIX is a time-dependant reaction 47,48. Many investigations have been 
made to determine how much time is required to ensure sufficient accumulation of  porphyrin 
to perform PDT. Some authors have used fluorescence investigations to find out when the 
highest contrast value is reached, i.e., when the highest concentration of PpIX has been 
achieved. Ericson et al. (2003)49 investigated BCCs using ALA and studied fluorescence 
contrast and threshold limits 1-4 hours after application time of ALA. It was shown that the 
highest contrast value between the BCCs and normal tissue was achieved with 3 hours pre-
treatment with ALA. In Europe this application time has become standard both with ALA and 
MAL. Later studies have questioned whether pre-treatment for 3 hours is really necessary. 
Braathen et al. 50performed a PDT-study of the AK cure rate, comparing 1.5 h application 
with 3 h application. They found that, although 1.5 h of application had slightly lower cure 
rate than 3 h, the cure rate was still sufficient. Sakamoto (2009)51 found a progressive increase 
of the contrast value for PpIX between 30 to 120 min after the application in an in vitro 
investigation on swine skin after topical application of ALA. Despite these publications 
further studies are needed before a shorter application time than the typical 3 hours could be 
recommended. 
 
1.4.2.5 Enhancing the penetration 
Penetration enhancement technology is presently developmental. The permeation of drugs 
through the skin can be enhanced either physically with iontophoresis (i.e., the application of 
low-level electric current), occlusion, excess of substance, tape-stripping/curettage; or 
chemically using permeation enhancers (CPE) with fatty acids, alcohols or terpenes which 
change the physicochemical structure of stratum corneum. Furthermore, for specific 
substances the interference may involve certain processes such as the iron chelators which 
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interfere with the haem biosynthesis in ALA-PDT44,52 and may increase the production of 
PpIX.  A high skin temperature, which increases the permeation of ALA, may also speed up 
the PpIX-production and the pH-level also influences the PpIX-production. However, none of 
the above mentioned measures are as yet in clinical practice53. 
 
The most common enhancer used clinically, with the exception of the removal of stratum 
corneum, is a 3 hour occlusion of the treated area an excess of the pro-drug, covered with a 
thin plastic film. 
 
1.4.3 Photophysics 
PDT can be divided into three main processes: sensitization, illumination and production of 
reactive oxygen species (ROS). All these processes are necessary to in the end finally cause 
tissue-death. The main treatment outcome of PDT is dependant on how much ROS such as 
singlet oxygen are produced in the cells54. To produce ROS, molecular oxygen and energy are 
required. Chromophores, like porphyrines, are able to absorb energy when irradiated by light 
55
. Different chromophores require different wavelengths according to their absorption 
spectra.  As all molecules strive to resume the ground state, energy is dissipated mainly by 
vibrational relaxation see figure 4, page 28. But to some extent fluorescence is obtained, i.e. 
the emission of longer wavelengths. For certain chormophores, such as porphyrins, energy 
can be transferred to surrounding molecular oxygen when trying to resume its ground state, 
resulting in the production of singlet oxygen. 
 
The absorption curve for PpIX has five peaks. The main peak, known as the Soret-band, 
absorbs the most energy at approximately 400 nm. There are 4 more peaks throughout the rest 
of the visible spectrum, these peaks are called the Q-bands, see figure 3.  
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Figure 3.  PpIX Absorption curve (not in scale) 
 
The longer the wavelength, the less energy is absorbed. When the PpIX has absorbed energy 
from the light it becomes excited from the ground state see figure 4. The PpIX quickly 
releases this energy in order to resume the ground state. . The PpIX fluoresces in the red part 
of the spectrum. However, for some molecules, energy from the donor PpIX is transferred to 
molecular oxygen forming singlet oxygen. The singlet oxygen will react with surrounding 
molecules. This causing the desired oxidative stress in PDT, ultimately destroying the tissue.  
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Figure 4.  Energy transfer at  PDT 
 
 
1.4.4 Photobleaching 
When light irradiates the photosensitizer PpIX, the formed singlet oxygen can react with the 
sensitizer itself in a photochemical reaction called photobleaching. In this reaction, the 
photosensitizer is consumed. Photobleaching is an oxygen-dependent process 56. This means 
that when the oxygen is depleated no photobleaching can take place. To monitor the 
photobleaching in vivo, fluorescence diagnostics can be performed as will be further discussed 
in section 1.5. Fluorescence images can be taken and image analyses can be used to calculate 
how much PpIX remains. Langmack et al. 57 proposed the idea that the rate of photobleaching 
is dependent on the fluence rate. 
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1.4.5 Dosimetry 
A specific dose (J/cm2, energy per unit area) is irradiated on the target, the dose is dependent 
on the fluence rate, i.e., if the Intensity = I (mW/cm2) and the treatment time ∆t then one can 
express the dose dependence as: 
 
 D = I ∆t 
 
The accumulated dose depends on which light source is used. Different light sources emit 
light over different spectral regions. When comparing two light sources with different spectral 
characteristics the total light dose will not be comparable, i.e., the dose for different light 
sources will depend on the phototherapeutic efficiency of the given spectral range they emit. 
The phototherapeutic efficiency of a light source can be defined as the number of excitations 
per second of the photosensitizer 58. It is therefore not easy to compare the dose between the 
different light sources without a thorough characterisation of the excitation efficiency of each 
source. There are different efficiencies for different light sources. The effective fluence light 
is defined as the light energy which is absorbed by the sensitizer. It should be noted, however, 
that some results have been described in the literature which show that high fluence rate is not 
to be recommended due to hyperthermia which seems to depleat oxygen more rapidly57,59. 
Light fractionation has been tested with positive results. Star (2006)60 saw that a two-fold 
PDT-illumination with a 2 hour dark interval between the two sessions gave a very high 
2 year complete remission. When de Haas (2008)61 investigated the fluorescence 
microscopically with fractionated light he was unable to fully explain the increased amount of 
PpIX between the two treatments.  However Puizina-Ivics (2008) 62 proposed that fractionated 
illumination may improve cure rates due to re-oxygenation between the fractionated 
treatments.  
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1.4.6 Light sources for PDT 
There are a wide range of different light sources that can be used for PDT. Both non-coherent  
light, e.g., example metallo-halogenes and light emitting diodes (LED), and coherent light, 
e.g., lasers, have been used. In recent years sunlight has also been investigated with good 
results 63,64. In some countries, for instance in the USA, blue light (405 nm) is used; while in 
Europe red light (635 nm) is favoured. The blue light has higher absorption by PpIX 
compared to red light; however the penetration of red light is better. The penetration depth 
(defined as the depth where the intensity has decreased to a factor 1/e) is only approximately 
0.1 mm for blue light into the epidermal tissue65,66, compared to values ranging from 
approximately 0.55 mm to 1/e 66 up to 5 mm65 for red light. 
 
Every light source has its advantages and disadvantages. Broadband and filtered non-coherent 
light sources have the advantage that they can be used to treat a large area at the same time, 
that they are easy to handle and inexpensive. The disadvantage of this treatment is the wide 
range of wavelengths.  
 
Monochromatic coherent light sources, such as lasers, have the advantage of using an exact 
wavelength. This is the preferred light source for fibre-optics, when internal organs are the 
target. The disadvantages are that they are expensive and only a small area can be treated at 
once.  
 
LED is a more recent light source which can be used both as diode lasers but also like non-
coherent light, the advantages being a narrower wavelength-band than metallo-halogenes. In 
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recent years an ambulatory low-irradiance organic LED light source has shown very 
successful results 67. 
 
1.4.7 PDT and pain 
Generally there are few side effects with PDT, the major side effect being pain. The treatment 
can be experienced as a very unusual burning or stinging sensation. Clinically the onset starts 
early during illumination and as treatment stops the pain decreases dramatically, but, in some 
cases it can last for 12-24 hours or more after conclusion of the treatment. The pain is usually 
measured by a VAS-scale ranging from 0 (no pain) to 10 (worst pain imagined).  
 
Grapengiesser et al. (2002)68 found that the level of pain is normally distributed among 
patients and risk factors for pain include: 1) size of the area treated, i.e., the larger the area 
treated the greater pain experienced, 2) diagnosis, i.e., AKs are often more painful to treat 
than BCCs and BDs, and 3) location of lesion, i.e., scalp, genital area and lips. Wiegell et al.69 
investigated fluorescence, which was found to be correlated to pain (the greater the 
accumulation of PpIX, the more pain). In the same study she also showed that lower fluence 
rate resulted in a lower experienced pain. Red light has been shown to be more painful to the 
patient than green light 70,  “high-output” broadband seems to be more painful than “low-
output” broadband 71, and finally fractionated light treatment has been demonstrated to be less 
painful 72 than non-fractionated. 
 
Over the years many attempts to reduce pain have been tried unsuccessfully including the 
application of topical local anaesthetics like morphine-gel 73, tetracaine-gel 74 and lidocaine-
prilocaingel 75 68.  
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Some papers have suggested that ALA is more painful than MAL76-78. The reason for this has 
been suggested to be due to the fact that ALA has an active transport into the cells which 
MAL does not have. Water, cold-packs, cold air analgesia (-35°C) and transcutaneous 
electrical nerve stimulation, TENS, have been administered with modest success 72,79,80 to 
alleviate the experience of pain in conjunction with the treatment.  
 
Recently successful treatment against pain has been found. Sub-cutaneous infiltration-
anaesthesia 81, nerve blocks 82,83, sun as a light source63 and ambulatory PDT using organic 
LED light source 67 have all shown good pain relief. Some of these treatments have 
disadvantages such as heavy oedema and the need for injections. Sunlight requires good 
weather, which makes planning difficult in countries which do not have a high frequency of 
sunlight. So far nerve blocks provide the most efficient pain relief during PDT for lesions on 
the scalp, face and genitals and the least disadvantages. Finally, good nursing and a friendly 
atmosphere during treatment have been shown to make PDT easier to tolerate. 
 
 
 
1.5. Fluorescence diagnostics (FD) 
1.5.1 Basic principles  
Fluorescence diagnostics is a non-invasive in vivo method used to selectively differentiate 
neoplastic tissue from healthy skin 84,85. As with PDT, FD uses the fact that tumour tissue has 
different properties compared to normal tissue; i.e., a destroyed outer barrier, more rapidly 
dividing cells, altered enzymes and possibly increased blood perfusion47. All these properties 
together enable tumour tissue to be distinguished from healthy tissue. The principles include 
excitation of fluorophores with light of a certain wavelength and afterwards the detection of 
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the fluorescence, either by endogenous fluorophores, autofluorescence, or by induced 
fluorescence, e.g., ALA induced fluorescence.  
 
The fluorescence diagnostics that we know it today has been developed lasting recent 
decades. However it was noted as early as 1924 when Policard reported red fluorescence 
obtained from a tumour on a rat by irradiation with Wood’s light 86 87 . After this finding, 
research was intensified. Spectroscopy was studied and sensitive spectrophotometers were 
developed, and using these, point measurements could be made88. With the development of 
charged coupled devices (CCD) connected to a computer it became possible to visualise the 
tumour using image analysis 89,90 see figure 5.  
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Figure 5.  Fluorescence diagnostics 
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Light sources to use in conjunction with ALA and MAL need to emit light in the UV-blue 
light range since their maximum absorption is at 405 nm. Both coherent, laser and non-
coherent light can be used, as described previously for PDT in section 1.4.6.  Which light 
source is used depends on the location of the organ to be treated; e.g., in hollow organs only 
lasers can be as these are suitable for use in optical fibres. For skin tumours both lasers and 
non-coherent light such as metallo-halogenes and LEDs may be used as some dispersion is 
not only allowed but may even be advantageous. As for PDT, the same advantages and 
disadvantages must be considered.  
 
Depending on the desired wavelength, a CCD-camera with different filters is most commonly 
used. Using this tool the intensity can be detected over a 2-dimensional area. The CCD-
camera is connected to a computer to make image analysis possible. The data consists of 
grey-scale images where each pixel value corresponds to the measured intensity value. This 
can be converted to a colour-scale showing certain colours if they have an intensity above a 
certain pre-defined value.   
 
The images captured by the CCD-camera are divided into pixels. The intensity of each pixel 
is then calculated. A threshold value is used to differentiate between the neoplastic tissue and 
normal tissue. To obtain this threshold value a reference marker is searched for to benchmark 
the value for normal tissue compared to the neoplastic tissue. The data are then normalised 
with respect to the reference marker. 
 
1.5.2 Autofluorescence 
Endogenous fluorescence or autofluorescence is based on the normal fluorophores that exist 
in the body and skin. Well known endogenous fluorophores are elastin, collagen, NADH, 
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keratin and tryptophan 91-93. Any given tissue has a mixture of many variable fluorophores and 
they are not uniformly distributed in the tissue. 
 
The architecture in normal and diseased tissue differs both in structural and metabolic 
composition85 . Examples of metabolic fluorophores are NADH-NAD+ and flavins and 
examples of structural fluorophores are collagen and elastin crosslinks in the dermal matrix. 
In  NMSC such as BCC and SCC, Brancalean et al.85 discovered in 2001 that endogenous 
fluorescence from tryptophan-residues was more intense in tumours due to tumour epidermal 
thickness or proliferation or both. Less fluorescence was seen from dermal collagen 
crosslinks, probably due to degradation or erosion of connective tissue, due to enzyme 
degradation from tumours. Therefore it was possible to selectively separate normal tissue 
from tumour tissue. When investigating autofluorescence the emission spectrum is in the 
green spectrum and is separated from the ALA-FD whose emission is in the red spectrum. 
 
1.5.2 ALA-induced fluorescence  
ALA or MAL is utilized in the same manner in FD as in PDT. Similarly to PDT, a 3h 
application time of the pro-drug is most commonly used to obtain as high concentration as 
possible within the tumour tissue while simultaneously avoiding any accumulation of PpIX-
concentration in the surrounding normal tissues. This is to ensure the contrast between the 
different tissues is as large as possible 49. It is necessary to receive as high a contrast value as 
possible between the neoplastic tissue and normal tissue to ensure that high resolution is 
achieved in the images 94. PpIX absorbs intensely at the Soret-band (380-420nm) with a peak 
at 405 nm (blue light) and fluoresces at round 630nm (red light). Thus UV-blue light is used 
as an excitation light source and causes the PpIX to fluoresce red light. A filter in front of the 
CCD-camera selects this wavelength and a fluorescence image is captured, see figure 5. This 
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image can be further analyzed to obtain additional information. A study of mouse skin by 
Moan (2001) 47 has previously suggested that MAL is more selective than ALA. de Bruijn  et 
al. 95 examined mouse skin with fluorescence microscopy in 2008 and found no difference 
between the two pro-drugs. 
 
1.6 Microdialysis 
Microdialysis (MD), is a method that has been widely used during the last decades. The 
method is based on passive diffusion. Low molecular weight substances passively diffuse 
through the semi-permeable membrane along a concentration gradient of compounds in extra-
cellular fluid. A small diameter probe containing a dialysis membrane is implanted into tissue 
and perfused with a suitable fluid. The catheter membrane has a molecular weight cut-off of a 
certain molecular size and therefore molecules smaller than this will be able to diffuse across 
the membrane into the perfusate. 
This technique was first applied in animal studies but later also on humans primarily to study 
brain function and changes in levels of endogenous compounds such as neurotransmitters or 
metabolites. The development of MD for the purpose of measuring drugs was initiated during 
the late eighties. Nowadays almost all tissues have been investigated, including brain tissue, 
skeletal tissue, muscles, subcutaneous adipose tissue, tendons, and skin among others 96,97. 
 
1.6.1 Microdialysis in the skin 
The MD technique can be applied for assessing percutaneous absorption in the skin98. It 
measures compounds in extra-cellular fluid over a semi-permeable membrane/filter of an 
MD-probe. The microdialysis catheter is guided into the dermis through a needle, thereafter 
the needle is removed with the catheter thus in place. To imitate the blood flow the catheter is 
connected to a precision pump which slowly perfuses it with a tissue-compatible sterile buffer 
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solution, see figure 1, page 3, of Paper III. Samples of the perfusate will be assessed for 
analysis at specified time intervals99. A problem with the insertion of the probe into the tissue 
is that it will elicit a tissue reaction, the flare reaction, causing changed skin circulation, which 
in turn can influence the skin metabolism100. Only a fraction of the substance will be 
recovered in the dialysate. The recovery depends on many factors, such as how long after the 
flare samples were collected, the perfusates’ properties, where and how the probe is situated 
and the substance qualities. In addition the MD-technique is not very suitable for lipophilic or 
highly protein-bound chemicals due to the small recovery101,102.  
 
The lipophilic substance can be trapped in the stratum corneum and the highly protein-bound 
complex will often be too large to pass across the semi-permeable membrane. 
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1.6.2 Calibration of the microdialysis technique 
Several articles have established a way to calibrate the MD-method and calculate the 
recovery103. The basis of the calculation is the assumption that the glucose or urea level is the 
same in the extra-cellular fluid as in the blood-plasma and that the in vivo recovery ratio for 
glucose or urea is the same as for the substance104, for example ALA, to be sampled. Then the 
relative recovery and the interstitional concentration of ALA( = I) can be calculated as: 
 
RR(ALA) in vitro                RR(ALA) in vivo 
─────────       =      ─────────
 
RR(Urea)
 in vitro                 RR(Urea) in vivo 
 
            Urea dialysate concentration 
RR(Urea) in vivo  =    ───────────────── 
     Urea plasma concentration 
 
 
          ALA dialysate concentration 
I  =    ───────────────── 
            RR(ALA) in vivo 
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2. AIMS OF INVESTIGATIONS 
 
The investigations conducted as part of the thesis have had the following aims: 
 
− to evaluate the impact of the fluence rate and spectral range on PDT for AKs 
 
− to register the distribution of pain during PDT of AK 
 
− to investigate which factors are related to pain during PDT of AK 
 
− to investigate the tumour penetration and interstitial concentration of ALA and MAL 
following topical application in BCCs in vivo using microdialysis 
 
− to evaluate the fluorescence contrast in patients treated with MAL-PDT for superficial 
BCCs and to compare the use of MAL with ALA as the pro-drug.  
 
− to find out whether poorly responding BCCs lack accumulation of PpIX after ALA and 
MAL application 
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3. PATIENTS AND METHODS  
 
3.1 Papers I-IV 
 
Paper I  
Patients 
A total of 40 patients, with clinically typical AKs, were included in an open, multi-centre, 
randomised study. Three patients were excluded from the analysis: one due to the lesion being 
diagnosed as a SCC and two due to equipment failure. In total 35 of the 37 lesions were 
histologically verified (32 men and 5 women, mean 71).  
 
Method 
Evaluation of the lesion and primary treatment outcome 
The AKs in the treatment area were drawn on a plastic film and the percentage of the AKs in 
relation to the total treatment area was calculated.  
 
Application of ALA cream 
ALA cream of 20% w/w δ-5-ALA-HCl in Unguentum-Merck® was applied in an 
approximately 1 mm thick layer for 3 h. A special occlusive bandage (Medeikonos AB, 
Sweden) 5 cm × 5 cm was used.  
 
PDT and fluorescence imaging 
PDT and FD equipment consisted of a non-coherent mercury lamp, Photodemarcation system 
1, Prototype 5 (Medeikonos AB, Sweden) with one arm for PDT and the other for FD. The 
arm for PDT was equipped with broad and narrow band filters. The broad band had a spectral 
range of 580 - 690 nm and the narrow band had a spectral range of 580 - 650 nm. The narrow 
filter produced two groups of fluence rates: 30 and 45 mW/cm2 (N30 and N45). The broad 
band filter also produced two groups of fluence rates: 50 and 75 mW/cm2 (B50, B75).  
 
The dose for all treatment groups was 100 J/cm2. The effective fluence rates were 
9.6 mW/cm2 (N30), 15 mW/cm2 (N45/B50) and 22 mW/cm2 (B75) (see 1.4.5 Dosimetry). 
The light for FD was concentrated to two peaks: 365 nm and 405 nm (UV-blue spectra), with 
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a fluence rate of 0.5 mW/cm2. The PDT was interrupted for fluorescence imaging at the 
accumulated doses of: 5, 10, 20, 40 J/cm2 and after the total dose of 100 J/cm2. 
 
Pain assessment 
After every interruption of the PDT-treatment, the patients were asked to record their 
maximum pain experienced during the previous PDT-session. The VAS-scale was graded 
from 0 (no pain) to 10 (worst pain imagined). 
 
Analysis of bleaching data 
Reference markers were used for normalisation. All data were collected from a cross-section 
including the reference markers and the AKs. This was completed for every image. The data 
were normalised using the reference markers. The cross-section data were then divided into 5-
10 regions. A mean value for every region was calculated. The mean value of bleaching data 
from all the 5-10 regions was calculated for each patient. Three patients were excluded from 
the analysis due to lack of reference markers and the inability to normalise the data from these 
images. A fourth patient was identified as a suspected outlier This patient was also excluded 
from the analysis.  
 
Follow-up 
After 7 weeks a follow-up visit was performed with an evaluation of the treatment response 
and remaining AKs were noted. 
 
 
Paper II 
Patients 
An open, multi-center, study including 94 patients with AKs (70 men and 24 women), ranging 
from 52-91 years of age with a mean of 76, were investigated to register pain levels 
experienced during PDT. All AKs were histologically confirmed. Three patients were 
excluded from the analysis, as two showed BD histologically and a third due to technical 
problems during the treatment. Therefore, 91 patients were deemed suitable for evaluation in 
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the study. Size, redness, scaling and induration were recorded. Maximum pain during 
treatment was measured using VAS as described previously. 
 
An additional pilot study was conducted on 7 patients (5 men and 2 women), of ages ranging 
between 50-81 years, mean 65, were included to test the pain reducing effect of pre-treatment 
with capsaicin. 
 
One patient discontinued the study due to local side-effects. Therefore 6 patients with a total 
of 10 lesions (1BD, 1superficial BCC, 8AKs) were deemed suitable for further analysis. 
 
Methods 
Photodynamic treatment 
ALA cream of 20% w/w δ-5-ALA-HCl in Unguentum-Merck® was applied in an 
approximately 1 mm thick layer over a 5 cm × 5 cm treatment area for 3 h under occlusion. 
Red light (590-650 nm) from a non-coherent light source (Photodemarcation System 1, 
Prototype 5 Medeikonos AB, Göteborg, Sweden) was used (dose 70J/cm2 and fluence rate of 
70 mW/cm2). Complete response was defined as clinically 0-1% remaining AK.  
 
In the pilot study, pre-treatment application with capsaicin cream on the treatment area was 
applied 3-5 times per day for 1 week before commencing PDT. Red light (600-730 nm) with a 
PDT 1200 lamp (Waldmann Medical, Schwenningen, Germany) was used.  
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Pain registration 
The pain was registered using VAS. The scale was divided into 3 groups: low or no pain, 
VAS 0-3; moderate pain, VAS 4-6; and severe pain, VAS 7-10. Fans and cold water spraying 
was offered, but no anesthesia was given during the treatment. 
 
Paper III 
 
Patients 
Twenty patients (4 women and 16 men), of age ranging between 51-93 years, mean 70, with 
27 BCCs (13 superficial, 14 nodular) were included. All lesions were histologically verified. 
The first ten patients were treated with MAL (13 BCCs, 8 nodular and 5 superficial), and the 
following ten patients received ALA (14 BCCs, 6 nodular and 8 superficial). Every second 
lesion was pre-treated with a light curettage (curettage: n=13, non-curettage: n=14).  
 
Methods 
Drugs 
20% w/w 5-ALA cream (in Unguentum-M®, Hermal, Reinbek, Germany) and 16% 
methylaminolaevulinate-cream (Metvix®, Photocure, Oslo, Norway) was applied to the 
BCCs in a 1 mm thick layer and then occluded for 3 h. 
 
Microdialysis procedure 
With guidance from a needle inserted intracutaneously, in or slightly under the BCCs, 
microdialysis catheters were inserted into the tumours at tissue depths varying between 0.4 to 
1.9 mm. The depth was measured with ultra-sound. A precision pump constantly perfused 
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physiological NaCl solution at a rate of 2 µl/minute. Dialysates were collected at 15-30 min 
intervals for 4 h. 
 
Chemical analysis 
 The interstitial concentrations of MAL and ALA were determined by the certified clinical 
chemistry laboratory at our university hospital using high-performance liquid chromatography 
(HPLC). A routine method for the determination of amino acid concentrations was used. The 
concentrations of ALA, MAL and 24 endogenous amino acids were determined for each 
sample. 
 
Calibration 
To estimate dermal interstitial ALA and MAL concentrations, the concentrations of 
microdialysed ALA and MAL were determined in vitro in blood plasma, to which three 
known concentrations of ALA and MAL were added. The in vitro recoveries of ALA and 
MAL were then calculated and found to be 4 ± 1 % and 6.3 ± 1.5 % respectively, see section 
1.6.2. 
 
Paper IV 
Patients 
Twenty-four patients, (13 male and 11 female) with ages ranging between 36-86 years, mean 
67, with one or more clinically suspected superficial BCCs, were included in this open 
prospective study. Two of the patients discontinued prematurely. Twenty-two patients with a 
total of 35 lesions were included in the analysis.  
 
44
 45
In a previous study by our group, the fluorescence of BCCs treated with ALA was 
investigated on forty patients with a total of forty lesions using the same fluorescence imaging 
device, as described below 49. 
 
Methods 
Drugs 
The MAL cream (160 mg/g, Metvix®, Photocure, Oslo, Norway) was administered to the 
tumour in an approximately 1 mm thick layer, including at least a 1 cm surrounding margin, 
and occluded for 3h. 
 
PDT-procedure 
The lesions had two sessions of PDT performed approximately one week apart with red light 
(approximately 635 nm, a fluence rate of 37 mW/cm2 and a total light dose of 37 J/cm2) using 
an LED-lamp (Actilite®, Photocure, Oslo, Norway).  
 
Assessment of pain 
The patients were asked to state the maximum pain experienced during both treatments using a 
visual analogue scale (VAS), ranging from 0 (no pain) to 10 (unbearable pain).  
 
Fluorescence diagnostics 
Fluorescence imaging was captured on all lesions immediately before the two sessions of 
irradiation. A Photodemarcation System 1, Prototype 5, (Medeikonos AB, Gothenburg, 
Sweden) with main excitation emissions of two peaks around 365 and 405 nm, having a 
fluence rate of 0.5 mW/cm2, was used. The detector consisted of a filtered CCD-camera with 
fluorescence emission in the range of 610–715 nm, matching the PpIX emission at 635 nm.  
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Follow-up 
The treatment outcome was assessed as: completely cleared, partially cleared (approximately 
50%) or not cleared, at a visit 7-18 weeks after the second treatment. Any adverse events were 
recorded.  
 
Image analysis 
On the digital clinical photographs, the clinical margins of the BCCs were marked by a 
clinician. The tumour margins in the fluorescence images were collected using a semi-
automated threshold algorithm implemented in Matlab®. After extracting the areas 
corresponding to the tumour area (T), normal MAL treated skin (N) and baseline (B) using 
the semi-automatic segmentation program, the mean intensity (I) in the selected regions was 
calculated. Thereafter, the fluorescence contrast, defined as: 
κ = IT/IN 
could be calculated. The area of the detected tumour region was also compared to the clinical 
tumour markings and their correlation was assessed.The mean fluorescence contrast obtained, 
after a 3 hour application of ALA, was calculated. In our earlier study on ALA 49, we 
calculated a peak contrast value including only 10% of the highest fluorescent pixels within 
the marked tumour area of all tumours.  
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3.2 Statistics 
Paper I 
To find out whether there were any differences between the groups, ANOVA and Student’s t-
test were used, two-tailed tests were applied and, to find potential outliers, the Dixon’s Q-test 
was utilized. To test for correlations, contingency tables were applied. 
 
Paper II 
To examine differences between two groups, independent t-test procedure was used. When 
comparing more than two groups, analysis of variance (ANOVA) and analysis of covariance 
(ANCOVA) were used. To analyse population distribution a Jarque Bera test using Matlab® 
Statistics Toolbox was applied. 
 
Paper III 
Student’s two-sample t-test, Fischer’s test and correlation coefficient methods were used. 
Mann Whitney U-test was applied to test for differences in distribution between groups.  
 
Paper IV 
Student’s t-test and Wilcoxon’s signed rank test were used as statistical methods. Pearson’s 
correlation coefficient and Spearman’s rho were used to test for correlations. Three 
fluorescence images were excluded from the analysis as the selected ROI were found to 
contain areas with field cancerization and actinic keratosis. Fluorescence contrast data are 
presented as mean values ± standard error of the mean (SEM) 
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3.3 Ethics  
Paper I  
The study was approved by the Ethical Committee of Linköping University  and was 
performed at the Departments of Dermatology at Sahlgrenska University Hospital 
(Gothenburg, Sweden), Karolinska Hospital (Stockholm, Sweden) and Linköping University 
Hospital (Linköping, Sweden).  
 
Paper II 
The local Ethics Committee of Linköping approved the study and the local Ethics Committee 
of Gothenburg approved the pilot study with capsaicin. Ten centres recruited the patients in 
the main study. All patients in the pilot study were recruited in Gothenburg. 
 
Paper III and Paper IV 
The studies were approved by the local Ethics Committee and performed at the Department of 
Dermatology and Venereology at Sahlgrenska University Hospital, Gothenburg, Sweden.  
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4. RESULTS 
 
4.1. Papers I-IV 
 
Paper I 
When comparing the 4 groups with different spectral emissions and fluence rates, it was 
found that the group with the narrow filter and 30 mW/cm2 (N30) had higher number of 
patients with complete remission compared to the other groups. 
 
The treatment outcome and fluence rate were found to correlate (p<0.02). The rate of 
photobleaching was also higher for the N30 group showing that the photobleaching is 
dependent on the fluence rate (see Table 2, p.1208, paper I). No significant difference was 
seen between the N45 and the B50 group with the same effective fluence rate (see section 
1.4.5 for definition), suggesting that it is the fluence rate and not the spectral range that is 
significant. No further photobleaching could be detected by the eye after a dose of 20 J/cm2, 
but when calculation was performed by the computer, slightly more photobleaching could be 
identified up to the dose of 40 J/cm2. No correlation between the fluence rate and pain could 
be observed, but it was observed that the pain increased up to 20 J/cm2 and then gradually 
decreased during the treatment up to 100 J/cm2 (see figure 5a, p. 1209, Paper I). 
 
Paper II 
It was noted that the pain was normally distributed (p=0.34) around a mean VAS value of 
visual analogue scale 4.6 although there was a large intervariation between the patients (see 
figure 1, p.405, Paper II). While there was a large group (31%, n=29) with no or low pain 
(VAS 0-3), a not negligible group ( 21%, n=19) had severe pain (VAS 7-10). Risk factors for 
pain were, larger lesions (p=0.001, see figure 2, p. 406, Paper II), the redness of the actinic 
lesions (p=0.01), and the reduction of the actinic area (p=0.007). Redness was also correlated 
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to the cure rate (p=0.01). The redder the actinic area, the better the treatment outcome and the 
more pain experienced. Patients with the largest reduction in the actinic area experienced 
more pain (p=0.053).  A trend was noted showing a more severe experience of pain in patients 
with skin type I-III (n=88) compared with those with skin type IV (n=3). However no 
statistical significance was reached (p=0.058).  
For those patients pre-treated with capsaicin no significant pain relief was noted. 
 
Paper III 
The location of the catheter depths in the two groups (ALA and MAL) was not found to be 
significantly different (P>0.18), although the depths for the ALA-catheters ranged from 0.4 to 
1.4 mm (n=14), and the MAL-catheters from 0.6 to 1.9 mm. During the 4 hour measurement 
period we could not find any significant difference in interstitial drug concentration between 
lesions treated with ALA or MAL. The mean concentration reached a plateau level after 15 
minutes. However, of 11 lesions in which the microdialysis catheter was located at a depth 
below 1 mm, drug concentrations above the detection limit were only obtained in 6 lesions, 
while 15 of 16 BCCs with a more superficial catheter location (i.e. less than 1 mm deep) 
exhibited detectable drug concentrations (p=0.026). Detectable levels of the drug were not 
obtained in almost 50% of the lesions where catheters were situated 1 to 1.9 mm in the lesion. 
The extra-cellular peak concentrations were reached within 90 minutes in 23 of the 27 BCCs, 
but were not found to be correlated with the depth of the catheters. Surprisingly the effect of 
curettage was found negligible and no difference could be identified between superficial and 
nodular BCCs.  
 
Paper IV 
The detected tumour area of superficial BCCs from the fluorescence images was found to be 
larger than the clinical border if the clinical tumour was less than 1 cm2, (see figure 3, p.26, 
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Paper IV). No significant difference in tumour area was observed when comparing the 
fluorescence images obtained before the first and second PDT sessions, (see figure 4, p. 27, 
Paper IV). As expected, the contrast between the MAL-treated normal skin and the non-
treated normal skin was significantly lower than the contrast between the MAL-treated 
tumour and MAL-treated normal skin. When comparing the contrast reached from the first 
and second treatment, this increased from 1.65 ± 0.06 to 1.84 ± 0.07 (p< 0.01). As 
fluorescence images from BCCs treated with ALA from a previous study49 were also 
available, it was possible to make a comparison between MAL and ALA. The mean 
fluorescence contrast obtained during the first treatment with MAL (1.65 ± 0.06) was 
significantly higher than the mean fluorescence contrast obtained after a 3 hour application of 
ALA (1.20 ±0.06) (p<10-4), (see figure 5, p. 28, Paper IV). In our previous study on ALA49, 
we calculated a peak contrast value including only 10% of the highest fluorescent pixels 
within the marked tumour area of all tumours. The value of the peak ALA contrast was found 
to be 1.61 ± 0.10. This value is similar to the mean contrast value obtained with MAL. Thus 
the mean contrast with MAL is as high as the peak contrast obtained with ALA.  
 
The cure rate was calculated at our follow-up visit, 7-18 weeks after the last treatment. We 
found that 91% (n=32) were completely cleared, 6% (n=2) were partially cleared and 3% 
(n=1) did not respond to PDT.  We also determined the fluorescence contrast and compared 
the completely cleared tumour area with the partial or non-cleared areas and found no 
correlation between the fluorescence and lack of treatment response. However, due to the 
small number of patients not responding to treatment in this study, no statistical analysis could 
be made. It was not possible to correlate the fluorescence obtained with the measured VAS 
(data not shown). 
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5. DISCUSSION 
 
5.1. Methodological considerations 
 
Paper I 
Fractionation of PDT may affect the treatment outcome. In our study the PDT was arrested 
for approximately 2 minutes between every dose investigated. During this time, the amount of 
PpIX would not have increased to a great extent since conversion to PpIX requires a greater 
period of time. The tissue would to some extent have been re-oxygenated in the break but this 
was the same for all fluence rates. 
 
A cross-section was analysed and not the whole area treated which might influence the results 
to some degree: but, since this methodology has been used to analyse all data, the relationship 
between the groups and results would only be marginally affected.  
 
In the study presented here all areas were calculated by hand which would introduce a small 
uncertainty. 
 
Fluorescence measures only the superficial PpIX and gives a measure of the amount deeper in 
the lesion. Our results may not be the true for the PpIX below surface levels. 
 
 
Paper II 
In the main study the field treated was small (5 cm × 5 cm). This area matched the light 
source treatment field which was available at the time when the study was performed. Taking 
into consideration that there are now light sources with treatment areas of 10 cm × 20 cm, this 
might affect the results of the assessment of the pain induced by the treatment if the study was 
re-run today, i.e., larger treatment areas tend to give larger pain. 
 
The pilot study aimed to analyse whether capsaicin had any pain reducing effect during 
illumination. All participating patients experienced the expected adverse events of 
erythematic skin and burning sensation in the treatment area after applying the capsaicin 
cream at home. Because of the pain experienced during application, one may question patient 
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drug compliance, which may have affected the final study result. The question was raised of 
extending the pre-treatment time with capsaicin to two weeks; but, the effect of this is 
questionable as the expected patient compliance due to pain experienced is low. The study 
would have been improved if we had selected patients with two areas needed to be treated at 
one time with one area receiving the cream and the other placebo-cream in a comparative 
study. 
 
 
Paper III 
The number of patients was limited due to the inconvenience to participate. All patients were 
required to lie down on their back for 8 hours during the measurements as all lesions studied 
had to be located on the front of the body. 
 
Calibration was made from blood plasma supplied from the hospital’s blood bank. The 
method may have been improved if the recovery had been calculated by analyzing an amino–
acid both from the blood and extra-cellular fluid directly from the patients’ plasma. 
 
There were difficulties with the insertion of the micro-dialysis catheters and to know in 
advance at what depth it would be inserted. The maximal catheter depth for BCCs treated 
with ALA was 1.4 mm and the maximal catheter depth for lesions treated with MAL was 
1.9 mm. The intention was of course to have the two groups as similar as possible. 
 
We could perhaps have used PDT to treat all patients, in order to be able to correlate the 
treatment outcome with the concentrations reached. However due to the inclusion of so many 
nodular BCCs, we chose to treat the BCCs according to recommended guidelines. 
 
 
Paper IV 
The clinical borders of the BCCs were marked on the digital photographs and not directly on 
the patients. It would have been easier to have marked the borders of the BCCs on the 
patients, but since we had performed a previous study where the borders were marked on the 
patients using a black ink pen and this disturbed the fluorescence images marking on the 
photos was chosen to minimise disturbance of the fluorescence images. 
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Fluorescence diagnostics only measures the superficial PpIX and does not show the amount of 
the PpIX in the deeper parts of the BCCs. If we had included thin nodular BCCs it may have 
been easier to evaluate any differences between the PpIX accumulation in the “difficult to 
treat” BCCs. 
 
In retrospect it might have been better to collect the ALA-data and the MAL-data at the same 
time. However as the equipment was used for the same procedures and the raw images were 
available from the previous study we concluded that this was not a major issue. 
 
 
5.2. General discussion 
 
PDT is a widely used method for a number of diagnoses today, some with excellent results 
such as thin NMSC like Bowen’s disease, AKs and superficial BCCs 105. These results are due 
to the right diagnosis for treatment but also to the use of the best treatment schedule. 
However, the method still needs to be refined to minimise unwanted side effects like pain, and 
the pre-treatment time with ALA and MAL which is inconveniently long. The cure rate for, 
e.g., nodular BCCs is somewhat low unless extensive debulking is used which then will 
interfere with the good cosmesis, which is one of the advantages of the method. 
 
Fluence rate, photobleaching and dose 
There are different treatment regimes for different light sources but also due to traditional 
hospital therapies. In the study in Paper I the photobleching was measured up to the dose of 
100 J/cm2, showing that doses above 40 J/cm2 did not demonstrate increased photobleaching, 
i.e., all PpIX was depleted. Thus, it seems unnecessary to use doses above 40 J/cm2 (635 nm, 
non-coherent light, Photodemarcation System 1). When reducing the dose to 40 J/cm2 with a 
low fluence rate, the treatment time could be decreased resulting in less pain.  
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We have demonstrated that it was favourable to use lower fluence rates for the treatment 
outcome as well as positively influencing the photobleaching. This seems to be explained by 
the oxygen depletion rate, which is slower with low fluence rate59. We showed that lower 
fluence rates resulted in lower bleaching doses. The bleaching dose was found to vary 
between the patients despite the fact that they were treated with the same fluence rate. The 
explanation for this might be that external factors are involved. For example, some patients 
are more anxious and may move during the treatment. The vascularisation is individual in all 
the patients as is the skin temperature which has earlier been shown to be influencing the 
PDT-treatment57.  
 
During the photobleaching of PpIX, formation of photoproducts takes place. It has been 
discussed whether these photoproducts are involved in the PDT process or not 106. It has also 
been speculated whether these photoproducts are involved in the pain or not. In the first study 
we included two types of spectral ranges. The broad spectrum included the absorption by the 
photoproducts around 670 nm, while the narrow spectrum excluded this absorption peak. The 
results from Paper I did not show any influence of the spectral range on either the pain, 
photobleaching or primary outcome. 
 
Pain 
The pain peak during PDT was reached early, i.e., within seconds or minutes and after 
20 J/cm2 it gradually decreased. After completion of the light therapy, the pain decreased 
radically (”like switching off a light”). Since later studies have showed that the pain is 
correlated to the PpIX-accumulation 69, the decrease of the pain might be explained by the 
fact that after the dose of 20 J/cm2, only a small part of the PpIX is left to photobleach. In this 
study, the photobleaching was high in the beginning of the treatment, but after the dose of 
10 J/cm2 the photobleaching rate decreased. Even if we cannot entirely explain the things that 
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take place, knowledge of the pattern is an important factor when informing the patient about 
the treatment and the known pain response, thereby bestowing a sense of security on the 
patient.  
 
Pain is the main disadvantage of PDT; other disadvantages are of minimal importance. During 
recent years research has focused on pain and pain-relieving strategies. Pain during PDT can 
sometimes be so severe that the patients either interrupt the treatment or endure the pain 
experiencing severe agony. It is therefore important to learn more about pain response during 
PDT.  
 
In paper II, pain experienced during PDT of actinic keratoses was investigated and we could 
confirm the results from our previous results, i.e., that pain is normally distributed in a Gauss 
curve68.  Of 91 patients included in the study, approximately 30% experienced VAS 0-3 while 
as many as 20% of the patients experienced VAS 7-10. This indicates the importance of 
identifying our search for better pain relieving strategies. We also confirmed that larger 
lesions gave more intense pain (Grapengiesser et al.68).  
A unique finding was a direct relationship between the redness, i.e., inflammation and 
vasodilatation of the lesion, which lead to increased pain but also improved treatment results. 
One theory is that in a vasodilated area available oxygen is increased which may lead to a 
better penetration of the pro-drugs. Furthermore, inflammatory diseases have also been treated 
with PDT with some effect, indicating that it may not only be the neoplastic cells which 
respond to treatment but also the inflammatory cells 107. Thus a larger number of cells will be 
damaged and may cause greater pain than when only the neoplastic cells are treated. Morton 
has previously mentioned his theory of “no pain, no gain”. In our study we found that patients 
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with the largest reduction in the actinic area experienced more pain (p=0.053), in support of 
Morton’s theory.  
 
To our disappointment, the capsaicin treatment as a pain reliever was not useful. Previous 
studies have shown that not only substance P is depleted but also that the nerve-endings are 
affected histologically after only 3 days of treatment with capsaicin at the same concentration 
(Wallergren and Håkansson 108). Nolano et al.109 performed a study, using capsaicin 0.075%, 
and showed a significant degeneration of nerve-fibres within a few days. One explanation for 
the lack of effect of the capsaicin treatment was that the compliance was not good and could 
have interfered with the results. This would certainly explain our findings but not exclude the 
need for more study to confirm the function of capsaicin. The patients included had 
previously experienced very severe pain during treatment, thus indicating the necessity for a 
stronger pain reliever. If patients with moderate pain had been included in the study it may 
have shown that the pain reliever could have had some effect. 
 
Difficulties with PDT 
There is an ongoing discussion concerning whether nodular BCCs are suited for PDT and 
how the pre-treatment should be performed. Previous studies have shown that the cure rate for 
nodular BCCs is lower than for superficial BCCs 38,110-112. Furthermore, one of the advantages 
with PDT is that it provides excellent cosmetic outcome. If extensive debulking is required for 
a tumour to be completely removed this will significantly affect the cosmetic outcome.  
 
The comparison between the two pro-drugs ALA and MAL is also interesting. In Paper III, 
we investigated both superficial and nodular BCCs and measured the amount of pro-drug 
required both with and without curettage. We could not find any significant difference in 
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concentration between the two pre-treatments. It should be noted that this is not in accordance 
with some previous results as described below.  
 
Van den Akker described in a study in 200343 that tape-stripping of normal nude mouse skin 
increased the PpIX-concentration implying that stratum corneum is an important barrier for 
the pro-drugs. Furthermore a study by Gerritsen44 and one by Smits et al.45 showed a negative 
correlation between thickness of stratum corneum and the amount of superficial PpIX 
measured indirectly by fluorescence diagnostics. One should note, however, that the 
diagnoses investigated were: normal skin, keratinocytic intraepidermal neoplasia, verrucous 
hyperkeratoses, actinic keratoses, i.e., not BCCs.  
 
Indeed our results are in accordance with a recent study performed by Moseley et al.46 who 
investigated superficial BCCs and BDs and who found no significant difference between 
tumours who had received curettage and those who had not, neither in measured superficial 
fluorescence nor in cure rate. 
One should keep in mind, however, that there may be an important difference due to the 
different diagnoses as in cases where the barrier for BCCs has already been broken there may 
be no need for pre-treatment.  
 
We found no difference between the transdermal penetration of ALA and MAL.  A plateau 
level of concentration was reached after 15 minutes. This is in agreement with another 
microdialysis study performed by Wennberg et al.42, where the rapid attainment of a plateau 
level of the concentration was noted. However, the measurements were performed no deeper 
than 0.5 mm.  
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In our microdialysis study, Paper III, the location of the catheters were measured by ultra-
sound to a depth between 0.4 - 1.9 mm. There was no problem with the penetration of the pro-
drugs to a depth of 1 mm. However, between 1 - 2 mm of depth, only about 50% of the 
measured lesions showed any concentration at all of the pro-drugs. If no concentration can be 
assessed, the question to be asked is “what will the cure rate be in those lesions”?  
 
There is pressure to have the pre-treatment time reduced, as the standard time for MAL is 3 
hours49. Lately Braathen et al.50 investigated PDT on AKs and used two groups of incubation 
times with MAL: 1 hour and 3 hours. The cure rate decreased slightly in the first group but 
the practical benefit of the shorter incubation time may make this treatment attractive. In our 
microdialysis study, we found that 23 out of 27 BCCs, reached their peak concentration 
within 90 minutes, but this was shown via measurements of the pro-drug in the extra-cellular 
space and not the PpIX within the cells. The results may still be an indication that shorter pre-
treatment time of the pro-drugs would not significantly effect the outcome of the treatment.  
 
Finally, we did not find any difference in penetration of the two pro-drugs between superficial 
and nodular BCCs. This is an indication that there is no tissue dependent difference between 
the penetrations of the pro-drugs. Instead it was discovered that the thickness of the BCC is 
very important. Most nodular BCCs are thicker than the superficial BCCs and this may be one 
explanation for the somewhat lower cure rate for the nodular BCCs. 
 
Fluorescence diagnostics 
Very few studies of FD have been performed comparing the pro-drugs ALA and MAL. One 
study in mouse skin by Moan et al.47 found that the ALA-induced fluorescence was visible 
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outside the topical treatment field while MAL-induced fluorescence was only seen in the 
treated field.  
 
In the final study presented within this thesis (Paper IV) we have analysed 37 BCC lesions 
on human skin in vivo, treated with MAL and compared it with a previous study using ALA 
as a pro-drug on 40 BCCs (also conducted on human skin in vivo) with the same equipment 
and procedure. Interesting data from the MAL-treated BCCs were obtained, evaluating the 
first and second PDT where the mean contrast increased from 1.65 ± 0.06 to 1.84 ± 0.07 at the 
second treatment (p< 0.01).  
This can most probably be explained by an increase in the penetration of the pro-drug, i.e. 
MAL, into the tumour due to disruption of the penetration barrier after the first treatment. 
This effect of PDT on the skin barrier function has previously been confirmed in rodents95. 
Another possible explanation for the higher PpIX accumulation in the tumour area at the 
second PDT session might be the presence of inflammatory cells as a result of the first 
treatment. Inflammatory cells have been reported to show high accumulation of PpIX after 
administration of ALA or MAL Thus, the presence of inflammatory cells at the second PDT 
session could contribute to the higher accumulation of PpIX in the tumour region95. 
 
The mean fluorescence contrast obtained during the first treatment with MAL (1.65 ± 0.06) 
was significantly higher than the mean fluorescence contrast obtained after a 3 hour 
application of ALA (1.20 ±0.06). In the published ALA-study49, we calculated a peak contrast 
value including only 10% of the highest fluorescent pixels within the marked areas, instead of 
a mean value, and this was found to be 1.61±0.10. This value is similar to the mean contrast 
value obtained with MAL. Thus, the mean contrast with MAL is as high as the peak contrast 
obtained with ALA. This implies that when performing FD, MAL is the treatment of choice. 
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This might be due to the fact that MAL, in contrast to ALA, is more selective and has only 
one pathway to be distributed into the tissue. Therefore it could take longer time before there 
will be any MAL outside the tumour area. 
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6. CONCLUSIONS 
 
Both the photobleaching rate and primary treatment outcome are dependant of fluence rate. A 
low fluence rate (30mW/cm2 ) seems preferable when performing PDT of AK using non-
coherent light sources. No influence of spectral range was seen, on the pain or primary 
treatment outcome 
 
The pain score was normally distributed around a mean value of VAS 4.6. 
 
The most important factors effecting pain during PDT seem to be the size and the redness of 
the lesion. 
 
No significant difference between the tumour penetration ability of ALA or MAL was found. 
Detectable levels of the drugs were obtained in only 50% of the lesions where catheters were 
placed > 1 mm deep. A pre-treatment curettage did not affect drug concentration. Thus 
penetration of the drug is uncertain when treating BCCs thicker than 1 mm. 
 
The fluorescent tumour area in small BCCs (<1 cm2) was larger than the clinically marked 
tumour. The mean tumour contrast was increased from 1.65 ± 0.06 at the first treatment, to 
1.84 ± 0.07 at the second treatment (p< 0.01). MAL renders a higher tumour contrast 
compared to ALA in superficial BCCs.  
 
No correlation between fluorescence and lack of treatment response could be observed.  
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7. OUTLOOK FOR THE FUTURE 
 
Both PDT and FD are relatively new techniques and need to be improved.  
 
Since there are difficulties with the penetration of the pro-drugs in the deeper regions of the 
tumours, new derivates, new delivery systems and transport media for the pro-drugs need to 
be found to increase penetration. Better delivery formulations could be cubic lipids 113,114. 
These would be interesting to test using the MD-technique. 
 
The pre-treatment time with ALA and MAL is too long to be convenient. If the delivery 
systems are changed further studies with shorter pre-treatment time would be interesting to 
perform also for other diagnoses than AK (Braathen50). Further investigations are necessary to 
calculate the time needed for the pro-drugs, ALA and MAL, to penetrate the lesions and to 
accumulate enough PpIX to successfully conduct PDT. This could possibly be tested by 
fluorescence microscopy on biopsies. 
 
A new ALA-patch delivery system 115 has been placed on the market, with the advantage that 
the patients do the pre-treatment at home and only enter the hospital for the irradiation with 
red light. Maybe with sufficient instruction the patients could also apply the cream with the 
pro-drug at home, making the inconvenience of the long pre-treatment time less.   
 
No further photobleaching could be detected by the eye after 20 J/cm2, but when calculation 
was performed by the computer a slightly increased photobleaching was detected up to 
40 J/cm2, but this is not the effective light dose.  
Today the standard dose for treating with an LED-source is 37 J/cm2. Since LED has a  
narrower spectrum than the lamp we used it is possible that we are over-treating these patients 
when treating superficial (pre)tumours like AK and SBCC. When considering the adverse 
side-effects such as pain, the reduction of the dose by half without interfering with the cure 
rate would lead to the treatment time being reduced to half. This would be an interesting study 
to perform. 
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The main disadvantage of PDT is pain. There have been many studies performed focusing on 
finding effective pain reducing treatments. The most effective treatment has recently been 
shown to be nerve blocks for pain relief of the face and scalp (Paoli et al., 2008 and Halldin et 
al., 2009) This treatment is, however, only available for the scalp, forehead, chin and medial 
cheek. For PDT to survive as a method of treatment in other areas of the body it is necessary 
to discover a successful pain relief treatment. A study designed to find new specific areas of 
the skin where peripheral nerve blocks maybe used is appealing. 
 
There is a need to improve the FD-method as it is not yet fully acceptable. Further study of 
the effect of combining the autofluorescence of BCC with the MAL-induced fluorescence, to 
increase the safety of FD use as a pre-surgical tool, would be a great asset and to use Mohs’ 
surgery to do control-mapping. 
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